The company has voluntarily recalled all lots of of human chorionic gonadotropin because of a lack of sterility assurance.
On Feb. 14, 2017, Synergy Rx Pharmacy announced a voluntary recall of all lots of of human chorionic gonadotropin (HCG) 5000 units/vial and 11,000 units/vial, distributed between June 1, 2016 and Dec. 22, 2016, because of a lack of sterility assurance. The recalled lots, which were packaged in 15 mL serum glass vials, were distributed to physician offices and clinics in Arizona, California, Wisconsin, and Minnesota.
As of Feb. 14, the company had not received any reports of adverse events due to the recalled product but it warns that use a product intended to be sterile that is not sterile could result in serious infections. The company is advising customers to stop use of the product and return any unused lots. Adverse events can be reported to FDA at www.fda.gov/medwatch/report.htm.
Source: FDA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.